Abstract
Background/Aim: Targeted intraoperative radiotherapy (TARGIT IORT) is an option during breast-conserving surgery (BCS). No data have yet been published regarding the safety of TARGIT IORT with implants in situ. TARGIT IORT is an attractive option in this context because of the risk of capsular fibrosis following external beam radiotherapy (EBRT) in such patients. Patients and Methods: We are reporting a retrospective analysis of 16 patients who received TARGIT IORT during BCS for early breast cancer after previous implant-based breast augmentation. TARGIT IORT was performed using the Intrabeam™method. Results: Follow-up varied from 98 to 5 months. There were no procedure-related complications. One patient developed local recurrence after 36 months of follow-up. Among the remaining patients (15/16), no breast-cancer-related events occurred. Conclusion: This series of patients with TARGIT IORT during BCS after implant-based breast augmentation revealed no safety concerns and gives some confidence in discussing this option with selected patients.
Footnotes
Authors' Contributions
HCK, VU and JSV developed the idea of this analysis. HCK, VU, SM, DH, GL, EWK contributed in the data collection. HCK, VU, SM, DH, GL, EWK, CKL and JSV contributed in analyzing the data and writing the manuscript.
This article is freely accessible online.
Conflicts of Interest
Dr. Kolberg reports personal fees from Carl Zeiss meditec, personal fees from Theraclion SE, personal fees from Genomic Health, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, non-financial support from LIV Pharma, personal fees from TEVA, personal fees from Riemser, personal fees from Janssen-Cilag, personal fees from Astra Zeneca, outside the submitted work. Dr. Uhl has nothing to disclose. Dr. Massarut reports other from Carl Zeiss meditec, outside the submitted work. Dr. Holmes has nothing to disclose. Dr. Kolberg-Liedtke has nothing to disclose. Dr. Whineray Kelly reports other from Focus Radiotherapy, outside the submitted work. Dr. Lövey has nothing to disclose. Dr. Vaidya reports personal fees and non-financial support from Carl Zeiss meditec, outside the submitted work.
- Received June 11, 2019.
- Revision received June 27, 2019.
- Accepted June 28, 2019.
- Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved